系统性红斑狼疮患者外周血造血干细胞水平的改变

Study on the Level of Peripheral Blood Hematopoietic Stem Cells in Patients with Systemic Lupus Erythematosus

目的:研究系统性红斑狼疮(SLE)患者外周血CD34+细胞和造血祖细胞(hematopoietic progenitor cells,HPC)水平与病情发展的关系。方法:采用BD FACSAria流式细胞分选仪测定系统性红斑狼疮患者(患者组)外周血中CD34+细胞水平,采用SysmexXE-2100型血液细胞分析仪测定SLE患者外周血中HPC水平,并设健康体检者对照(对照组)。结果:患者组在活动期时,CD34+细胞水平(0.178±0.044)%高于稳定期时CD34+细胞水平(0.044±0.020)%,差别有统计学意义(P<0.01),SLE患者稳定期CD34+细胞水平与对照组CD34+细胞水平(0.038±0.016)%间差异无统计学意义(P>0.05)。复发组CD34+细胞水平(0.210±0.052)%高于未复发组CD34+细胞水平(0.042±0.028)%,差别有统计学意义(P<0.01)。HPC测定显示同样的变化趋势。结论:系统性红斑狼疮患者外周血CD34+细胞和HPC的水平变化与病情发展密切相关,监测外周血CD34+细胞和HPC水平可有效地评估SLE患者病情发展和疗效。

Objective： Study on the relationship between the levels of CD34^＋ and hematopoietic progenitor cells （HPC） and the process of the pathology in patients with systemic lupus erythematosus （SLE）. Methods; The level of CD34^＋ cells was measured by the BD FACSAria flow cytometer in patients with SLE. The level of HPC was detected by Sysmex XE- 2100 in patients with SLE. Results： The level of CD34^＋ cell（0.178±0.044）% was significantly increased in the patients of activated stage compared to that in patients with the stable stage [（0.044 ±0.020）% ,P 〈 0.01 ）. There was no significant changes between the level of CD34^＋ cell in patients of stable stage （0.044 ±0.020）% and the controls[（0.038±0.016）% ,P〉 0.05]. There was a significant higher level of CD34^＋ cell in recrudescence group （0.210±0.052）% than that of nonrecrudescence group [（0.042 ±0.028）% ,P 〈 0.01]. There were similar results for HPC between two groups. Conclusion： There was strong relationship between the levels of CD34^＋, HPC and pathology process in SLE patients. By detecting the levels of CD34^＋ and HPC, it could be possible to assess the development trend and medical effect in SLE patients.